Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.52 |
| ▸ | MAOA | P21397 | 9/20 | 0.52 |
| ▸ | RXRA | P19793 | 3/20 | 0.46 |
| ▸ | RXRB | P28702 | 3/20 | 0.46 |
| ▸ | RXRG | P48443 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432831 | 0.89 | CYP19A1 (0.51) | MAPTALDH1A1CYP19A1CYP11B2KMT2A | |
| SCHEMBL3004692 | 0.89 | CYP19A1 (0.51) | MAPTALDH1A1CYP19A1CYP11B2KMT2A | |
| SCHEMBL3854161 | 0.87 | MAOA (0.53) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL3966174 | 0.84 | MAOB (0.51) | MAOBMAOAALDH1A1CYP19A1CYP11B2 | |
| SCHEMBL3966171 | 0.84 | MAOB (0.51) | MAOBMAOAALDH1A1CYP19A1CYP11B2 | |
| SCHEMBL13110402 | 0.82 | MAOA (0.48) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL821438 | 0.82 | NQO2 (0.49) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL16048803 | 0.82 | NQO2 (0.49) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9290663 | 0.80 | NQO2 (0.53) | MAOBRXRANPC1RAB9AMAPT | |
| SCHEMBL8514302 | 0.80 | NQO2 (0.53) | MAOBRXRANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7582803-B2 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582803-B2 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | MAOB 1610/4885MAOA 1264/4885RXRA 218/4885 |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | GOT2, PC, GOT1 | MAOB 603/4885MAOA 737/4885RXRA 528/4885 |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | MAOB 1610/4885MAOA 1264/4885RXRA 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.